Anti-müllerian hormone is not associated with cardiometabolic risk factors in adolescent females

Abstract (VSports最新版本)

Objectives: Epidemiological evidence for associations of Anti-Müllerian hormone (AMH) with cardiometabolic risk factors is lacking. Existing evidence comes from small studies in select adult populations, and findings are conflicting. We aimed to assess whether AMH is associated with cardiometabolic risk factors in a general population of adolescent females.

Methods: AMH, fasting insulin, glucose, HDLc, LDLc, triglycerides and C-reactive protein (CRP) were measured at a mean age 15. 5 years in 1,308 female participants in the Avon Longitudinal Study of Parents and Children (ALSPAC). Multivariable linear regression was used to examine associations of AMH with these cardiometabolic outcomes VSports app下载.

Results: AMH values ranged from 0. 16–35. 84 ng/ml and median AMH was 3. 57 ng/ml (IQR: 2. 41, 5. 49). For females classified as post-pubertal (n = 848) at the time of assessment median (IQR) AMH was 3. 81 ng/ml (2. 55, 5. 82) compared with 3. 25 ng/ml (2. 23, 5. 05) in those classed as early pubertal (n = 460, P≤0. 001). After adjusting for birth weight, gestational age, pubertal stage, age, ethnicity, socioeconomic position, adiposity and use of hormonal contraceptives, there were no associations with any of the cardiometabolic outcomes. For example fasting insulin changed by 0% per doubling of AMH (95%CI: −3%,+2%) p = 0. 70, with identical results if HOMA-IR was used. Results were similar after additional adjustment for smoking, physical activity and age at menarche, after exclusion of 3% of females with the highest AMH values, after excluding those that had not started menarche and after excluding those using hormonal contraceptives.

Conclusion: Our results suggest that in healthy adolescent females, AMH is not associated with cardiometabolic risk factors.